What question did this study set out to answer?

To assess health status improvements in symptomatic heart failure patients on SGLT2 inhibitors using the KCCQ-12 questionnaire.

January 10, 20260 citationsOpen Access

Assessment of Health Status of Patients with Symptomatic Heart Failure Receiving SGLT2 inhibitors using KCCQ12

I(International Journal of Medical Science and Innovative Research (IJMSIR)

Key Result

SGLT2 inhibitors led to a cumulative improvement of 60.4% in health status among patients with HFrEF, significantly enhancing quality of life and reducing symptom burden.

Key Points

To assess health status improvements in symptomatic heart failure patients on SGLT2 inhibitors using the KCCQ-12 questionnaire.
Conducted a prospective case-control study at GSVM Medical College, Kanpur.
Enrolled 84 patients with heart failure and assessed them at three visits: baseline, one month after care, and six months of SGLT2 treatment.
Analyzed KCCQ-12 scores using paired t-tests and Wilcoxon signed-rank tests.
Observed significant improvements in all KCCQ-12 domains after six months of therapy.
Initial improvements of around 31% from Visit 1 to Visit 2 and an additional 17.6% from Visit 2 to Visit 3.
Total cumulative improvement from Visit 1 to Visit 3 ranged from 54-62% across domains, confirming statistical significance (p<0.0001).

Structured PICO

Does dapagliflozin improve patient-reported health status (KCCQ-12 scores) in patients with symptomatic HFrEF?

Population

84 adults (age >40 years) with symptomatic heart failure with reduced ejection fraction (HFrEF, LVEF <40%, NYHA class II-IV) and NT-proBNP >300 pg/ml (>600 pg/ml if atrial fibrillation/flutter), based in North India.

Intervention

Dapagliflozin 10 mg oral once daily added to standard treatment of care for 6 months.

Comparator

Standard treatment of care alone (assessed after 1 month prior to adding dapagliflozin).

Outcome

Health status assessed by KCCQ-12 domain scores (Physical Limitations, Social Limitations, Symptom Frequency, and Quality of Life) at 6 months.patient reported

Dapagliflozin added to standard care significantly improves patient-reported health status, symptom burden, and quality of life in Indian patients with symptomatic HFrEF.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Abstract Heart failure with reduced ejection fraction (HFrEF) remains a major public health challenge, leading to significant morbidity and mortality. The Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) is a validated tool for assessing the health status of heart failure patients. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a novel therapeutic approach, improving cardiovascular outcomes. However, their impact on patient-reported quality of life needs further evaluation, especially in the Indian population. Objective: To evaluate the health status of patients with symptomatic HFrEF receiving SGLT2 inhibitors using KCCQ-12, focusing on improvements in physical limitations, symptom frequency, quality of life, and social limitations. Methods: A prospective case-control study was conducted at GSVM Medical College, Kanpur, over two years. A total of 84 patients with HFrEF were enrolled and assessed at three visits: baseline (Visit 1), after one month of standard care (Visit 2), and after six months of SGLT2 inhibitor therapy (Visit 3). KCCQ-12 domain scores were analysed using paired t-tests and Wilcoxon signed-rank tests. Results: Significant improvements were observed in all KCCQ-12 domains Domains V1 →V2 (%) V2 → V3 (%) Cumulative V1 → V3 (%) SS 31.1 17.5 60.4 SF 31.1 17.6 60.4 PL 31.1 17.6 60.4 SL 31.0 17.7 60.2 QL 31.1 17.6 60.4 Improvement Patterns Visit 1→2: Consistent ~31% improvement across all domains, reflecting strong initial treatment response. Visit 2→3: ~17.6% further gains, showing continued but slower progression. SF/PL equivalence: Identical trajectories confirm these domains measure overlapping constructs in this cohort. Total cumulative improvement from Visit 1 to 3 ranged 54-62% across domains, with paired t-tests confirming statistical significance (p<0.0001) for both intervals. This result correlating with improved functional and symptomatic status. Conclusion: SGLT2 inhibitors significantly enhance the quality of life, reduce symptom burden, and improve functional capacity in patients with HFrEF, as measured by KCCQ-12. These findings reinforce their role as an essential therapy in heart failure management.

问 AI

Bookmark

View Full Paper